myelin peptide-loaded tolerogenic dendritic cells

Myelin peptide-loaded tolerogenic dendritic cells (tolDCs) are an autologous cell-based immunotherapy developed by Antwerp University Hospital for the treatment of multiple sclerosis. The therapy involves the ex vivo differentiation of a patient's monocytes into dendritic cells, which are then treated with 1,25-dihydroxyvitamin D3 to induce a stable tolerogenic phenotype. These cells are subsequently loaded with a cocktail of seven myelin-derived peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP). When administered intradermally, these tolDCs are designed to migrate to the lymph nodes and present the myelin antigens to autoreactive T cells in a non-inflammatory context. This process aims to induce antigen-specific immune tolerance, potentially through the induction of regulatory T cells or the promotion of T cell anergy, thereby halting the autoimmune destruction of the myelin sheath in the central nervous system.

Other names

autologous myelin peptide-loaded tolerogenic dendritic cellsvitamin D3-treated tolerogenic dendritic cellsmyelin-antigen-loaded tolerogenic dendritic cells